gdc
PSSGuide_2021
Ovarian Cancer

Drugs for Ovarian Cancer/Endometrial (Uterine) Cancer

Here are the drugs and financial support services available to patients receiving treatment for Ovarian Cancer.

Avastin (bevacizumab) Injection

Drug company: Genentech
866-422-2377

Avastin is a VEGF-specific angiogenesis inhibitor used for the treatment of patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer, in combination with carboplatin and paclitaxel, followed by Avastin alone, in patients with stage III or IV disease after surgical resection; in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease after 2 or less previous chemotherapy regimens; and in combination with carboplatin and paclitaxel, or carboplatin and gemcitabine, after Avastin alone, for patients with platinum-sensitive, recurrent disease.

Genentech Oncology offers 2 financial assistance programs for patients using Avastin:

Genentech Oncology Co-pay Assistance Program

Eligible patients with private insurance will pay just a $5 copay per prescription or infusion of Avastin, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 180 days before enrollment in this program.

Genentech Patient Foundation

This foundation provides Avastin free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria.

Gemzar (gemcitabine)

Drug company: Eli Lilly
866-472-8663

Gemzar is a nucleoside metabolic inhibitor used, in combination with carboplatin, for the treatment of patients with advanced ovarian cancer.

Lilly Oncology does not currently provide a specific financial assistance program for Gemzar.

Hexalen (altretamine)

Drug company: Eisai
888-274-2378

Hexalen is an antineoplastic medication used for palliative treatment in patients with ovarian cancer.

Eisai does not currently offer financial assistance programs for Hexalen. However, Eisai has partnered with Rx Outreach to provide medications at a low cost for patients with financial needs who are using Hexalen and meet the program eligibility criteria. For more information, e-mail This email address is being protected from spambots. You need JavaScript enabled to view it. or call 800-769-3880.

Hycamtin (topotecan) Injection

Drug company: Novartis
800-245-5356

Hycamtin for injection is a topoisomerase inhibitor used for the treatment of patients with metastatic carcinoma of the ovary.

Novartis’ Patient Assistance NOW Oncology offers 1 financial assistance program for patients using Hycamtin:

Novartis Patient Assistance Foundation

Patients who are experiencing financial hardship and have limited or no public or private prescription coverage may be able to receive Hycamtin for free through the Novartis Patient Assistance Foundation. To be eligible for financial support, the patient must be a US citizen and must provide proof of income that meets the financial eligibility requirements. Eligible patients may receive Hycamtin for free until prescription drug coverage becomes available to them.

Lynparza (olaparib) Capsules/Tablets

Drug company: AstraZeneca
844-275-2360

Lynparza is a PARP inhibitor used for the maintenance treatment of patients with recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy, and for the treatment of patients with advanced ovarian cancer associated with deleterious or suspected deleterious germline BRCA mutation, after 3 or more chemotherapies. Lynparza is also used for the maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy, and as first-line maintenance treatment, in combination with bevacizumab, of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with HRD status, defined by a deleterious or suspected deleterious BRCA mutation and/ or genomic instability, as detected by an FDA-approved test.

AstraZeneca offers 2 financial assistance programs for patients using Lynparza:

Lynparza Co-pay Savings Program

Although out-of-pocket costs may vary, this program aims for eligible patients to pay $0 monthly for Lynparza, with a maximum out-of-pocket savings of $26,000 annually. This program has no income requirements, but eligible patients must have private health insurance that partially covers the medication costs for Lynparza.

AZ&Me Prescription Savings Program

This prescription savings program offers free, mail-based medication to qualifying patients who have no insurance, those who have Medicare Part D coverage, and some patients with Medicare Part B coverage. General eligibility requirements include limited household income and/or a life-changing event in the past year that affected the patient’s finances. Patients with Medicare Part D coverage must spend 3% of their total household income on prescription medicines through a Medicare Part D prescription plan during the current calendar year and must be unable to enroll in Medicare Limited Income Subsidy. Patients with Medicare Part B coverage should call 800-292-6363 for program requirements. Once accepted into the program, patients will be enrolled for 1 year (with the option to re-enroll) and a supply of Lynparza (up to 90 days) will be sent directly to the patient. Refills need to be requested by the doctor or the patient.

Rubraca (rucaparib) Tablets

Drug company: Clovis Oncology
844-779-7707

Rubraca is a PARP inhibitor used as monotherapy for the treatment of patients with advanced ovarian cancer associated with deleterious BRCA mutation (germline and/or somatic) who received 2 or more chemotherapies, and for maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients whose disease is in complete or partial response to platinum-based chemotherapy. Rubraca is also used for the maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

Clovis Oncology offers 3 financial assistance programs for patients using Rubraca:

Rubraca $0 Co-Pay Program

Patients with private insurance pay $0 copay for Rubraca through this program, with maximum annual assistance up to $30,000.

Rubraca Connections Patient Assistance Program

Patients who are uninsured or underinsured who meet certain financial and residential eligibility requirements may qualify to receive Rubraca for free.

Rubraca Connections QuickStart Program

Patients with private, commercial, or government insurance who are experiencing delays in medication coverage may be eligible to receive Rubraca at no cost for the first 15 days of treatment, up to 3 refills (maximum 60 days).

Zejula (niraparib) Capsules

Drug company: GlaxoSmithKline
844-447-5662

Zejula is a PARP inhibitor used as a maintenance (continuing) treatment for adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer after a complete or partial response to platinum-based chemotherapy. Zejula is also used for the treatment of adults with advanced ovarian, fallopian tube, or primary peritoneal cancer after at least 3 previous chemotherapy regimens, whose cancer is associated with HRD-positive status, defined by a deleterious or suspected deleterious BRCA mutation, or by genomic instability and whose disease progressed more than 6 months after response to the last platinum-based chemotherapy.

GSK Oncology offers 2 financial assistance programs for patients who have been prescribed Zejula:

Together with GSK Oncology Commercial Copay Program

Through this program, eligible patients who have private insurance can pay as little as $0 for Zejula, with a maximum benefit of $26,000 annually.

Patient Assistance Program

Eligible patients who are uninsured or underinsured may receive Zejula for free through this program. Qualified patients must have a maximum monthly household gross income of $5,316.67 for individuals, $7,183.33 for a family of 2, $9,050.00 for a family of 3, $10,916.67 for a family of 4, and $1,866.67 for each additional person.

Endometrial (Uterine) Cancer

Keytruda (pembrolizumab)

Drug company: Merck
855-257-3932

Keytruda is a PD-1 inhibitor used, in combination with Lenvima (lenvatinib), for the treatment of patients with advanced endometrial carcinoma without microsatellite instability-high (MSI-H) abnormality or deficient-mismatch repair (dMMR), whose disease progressed after previous systemic therapy and who are not candidates for curative surgery or radiation.

Merck offers 2 financial assistance programs for patients using Keytruda:

Merck Co-pay Assistance Program

Privately insured patients will pay the first $25 of their copay per Keytruda infusion. The maximum benefit per calendar year is $25,000 for patients with an income level up to 700% of the federal poverty level, and $10,000 for patients with an income above 700% of the federal poverty level.

Merck Patient Assistance Program

Patients without insurance or prescription coverage may be eligible to receive Keytruda at no cost. Eligible patients must have a household income of $63,800 or less for individuals, $86,200 or less for a couple, or $131,000 or less for a family of 4. Patients with insurance, including Medicare Part D, who still have trouble paying for their medicines may request that an exception be made, provided their household income is not above a set limit.

Lenvima (lenvatinib) Capsules

Drug company: Eisai
866-613-4724

Lenvima is a kinase inhibitor used, in combination with Keytruda, for the treatment of patients with advanced endometrial carcinoma without microsatellite instability-high (MSI-H) abnormality or mismatch repair-deficient (dMMR), whose disease progressed after previous systemic therapy and who are not candidates for curative surgery or radiation.

Eisai offers 2 financial assistance programs for patients using Lenvima:

Lenvima $0 Co-Pay Program

Privately insured patients may be eligible for this program, which offers a $0 copay for each prescription, with a $40,000 annual limit.

Eisai Patient Assistance Program

This program provides Lenvima at no cost to patients with financial needs who meet the program’s eligibility criteria.

Table. Drugs Prescribed for Ovarian Cancer

  • Drug name (generic name)
  • Drug company
  • Indications
  • Patient support services
    Drug name (generic name)
  • Avastin (bevacizumab) Injection
  • Drug company
  • Genentech
  • Indication
  • Treatment of patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer, in combination with carboplatin and paclitaxel, followed by Avastin alone, in patients with stage III or IV disease after surgical resection

    Treatment of patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease after 2 or less previous chemotherapy regimens

    Treatment of patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer, in combination with carboplatin and paclitaxel, or carboplatin and gemcitabine, after Avastin alone, for patients with platinum-sensitive, recurrent disease
  • Patient support services
  • Genentech Oncology Co-pay Assistance Program
    855-692-6729

    Genentech Patient Foundation
    888-941-3331

    Drug name (generic name)
  • Gemzar (gemcitabine)
  • Drug company
  • Eli Lilly
  • Indication
  • Advanced ovarian cancer, in combination with carboplatin
  • Patient support services
  • (No specific program)
    866-472-8663

    Drug name (generic name)
  • Hexalen (altretamine)
  • Drug company
  • Eisai
  • Indication
  • Ovarian cancer
  • Patient support services
  • This email address is being protected from spambots. You need JavaScript enabled to view it.
    800-769-3880

    Drug name (generic name)
  • Hycamtin (topotecan) Injection
  • Drug company
  • Novartis
  • Indication
  • Metastatic carcinoma of the ovary
  • Patient support services
  • Novartis Patient Assistance Foundation
    800-277-2254

    Drug name (generic name)
  • Lynparza (olaparib) Capsules/Tablets
  • Drug company
  • AstraZeneca
  • Indication
  • Maintenance therapy in adults with recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, after complete or partial response to platinum-based chemotherapy

    Adults with advanced ovarian cancer and deleterious or suspected deleterious germline BRCA mutation, after 3 or more lines of chemotherapy Maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy

    First-line maintenance treatment, in combination with bevacizumab, of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to firstline platinum-based chemotherapy

    and whose cancer is associated with HRD status, defined by a deleterious or suspected deleterious BRCA mutation and/or genomic instability, as detected by an FDA-approved test
  • Patient support services
  • Lynparza Co-pay Savings Program
    844-275-2360

    AZ&Me Prescription Savings Program
    800-292-6363

    Drug name (generic name)
  • Rubraca (rucaparib) Tablets
  • Drug company
  • Clovis Oncology
  • Indication
  • Advanced ovarian cancer with deleterious BRCA mutation (germline and/or somatic) after 2 or more chemotherapies

    Maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients whose disease is in complete or partial response to platinum-based chemotherapy

    Maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy
  • Patient support services
  • Rubraca $0 Co-Pay Program
    844-779-7707

    Rubraca Connections Patient Assistance Program
    844-779-7707

    Rubraca Connections QuickStart Program
    844-779-7707

    Drug name (generic name)
  • Zejula (niraparib) Capsules
  • Drug company
  • GSK Oncology
  • Indication
  • Treatment for adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer after a complete or partial response to platinum-based chemotherapy

    Treatment of adults with advanced ovarian, fallopian tube, or primary peritoneal cancer after at least 3 previous chemotherapy regimens, whose cancer is associated with HRD-positive status, defined by a deleterious or suspected deleterious BRCA mutation, or by genomic instability, and whose disease progressed more than 6 months after responding to the last platinum-based chemotherapy
  • Patient support services
  • Together with GSK Oncology Commercial Co-pay Program
    844-447-5662

    Patient Assistance Program
    844-447-5662
Endometrial (Uterine) Cancer
  • Drug name (generic name)
  • Drug company
  • Indications
  • Patient support services
    Drug name (generic name)
  • Keytruda (pembrolizumab)
  • Drug company
  • Merck
  • Indication
  • Treatment, in combination with lenvatinib, of patients with advanced endometrial carcinoma without MSI-H abnormality or dMMR, whose disease progressed after systemic therapy and who are not candidates for curative surgery or radiation
  • Patient support services
  • Merck Co-pay Assistance Program
    855-257-3932

    Merck Patient Assistance Program
    800-727-5400

    Drug name (generic name)
  • Lenvima (lenvatinib) Capsules
  • Drug company
  • Eisai
  • Indication
  • Treatment of patients with advanced endometrial carcinoma without MSI-H abnormality or dMMR, whose disease progressed after previous systemic therapy and who are not candidates for curative surgery or radiation, in combination with Keytruda
  • Patient support services
  • Lenvima $0 Co-Pay Program
    866-613-4724

    Eisai Patient Assistance Program
    866-613-4724
dMMR indicates mismatch repair-deficient; MSI-H, microsatellite instability-high.

Share this:

Last modified: April 7, 2021

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country